Hikma Pharmaceuticals

Historical price data

Hikma Pharmaceuticals is a revenue-generating, publicly traded pharmaceutical company with a mission to improve global access to high-quality medicines. It operates through three distinct, market-leading segments: a top-five global Injectables business, a rapidly growing US-focused Generics (Hikma Rx) division, and a Branded business that is the largest pharmaceutical company by sales in the MENA region. The company's strategy focuses on striving for operational excellence, diversifying its product pipeline, and empowering its people, supported by a culture of innovation, caring, and collaboration. Recent achievements include launching 84 products in 2025 and implementing strategic investments to drive future growth.

Hikma's core platform is its vertically integrated global manufacturing and complex formulation expertise, specializing in difficult-to-produce sterile injectables and generic medicines, supported by extensive R&D focused on bioequivalence and process development.

Hikma competes with large global generics firms (e.g., Viatris, Teva) in Injectables and US Generics, and with multinational pharma companies (e.g., GSK, Sanofi) in MENA. Its competitive edge stems from vertical integration, complex formulation expertise, and deep regional commercial presence.